Lindsey Rolfe
Direktor/Vorstandsmitglied bei ATRECA, INC.
Vermögen: - $ am 30.04.2024
Aktive Positionen von Lindsey Rolfe
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ATRECA, INC. | Direktor/Vorstandsmitglied | 22.08.2019 | - |
Independent Dir/Board Member | 22.08.2019 | - | |
The Royal College of Physicians | Corporate Officer/Principal | - | - |
Karriereverlauf von Lindsey Rolfe
Ehemalige bekannte Positionen von Lindsey Rolfe
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CLOVIS ONCOLOGY, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.08.2015 | 01.06.2023 |
Corporate Officer/Principal | 01.04.2010 | 01.08.2015 |
Ausbildung von Lindsey Rolfe
The University of Edinburgh | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 3 |
Vereinigtes Königreich | 3 |
Operativ
Director/Board Member | 2 |
Corporate Officer/Principal | 2 |
Independent Dir/Board Member | 2 |
Sektoral
Health Technology | 3 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ATRECA, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Börse
- Insiders
- Lindsey Rolfe
- Erfahrung